Monitor for protocol finalization and trial initiation, which could catalyze partnership interest and revaluation. Positive trial results could lead to accelerated approval with substantial commercial upside in a niche but high-need indication.
Price Chart
Executive Summary
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design for pelareorep in metastatic squamous cell carcinoma of the anal canal (SCAC), a rare cancer with no approved therapies post-first-line treatment. The study leverages strong prior data showing improved duration of response and survival versus standard of care.
Key Facts
- FDA alignment achieved on pivotal randomized controlled trial for pelareorep in metastatic SCAC
- Study targets post-standard-of-care population with no FDA-approved options
- Prior data showed 15.5 vs 9.5 month median duration of response and 82% vs 45.7% 12-month survival vs standard of care
- Trial design may support both accelerated and full approval
- Pelareorep already has Fast Track designation for colorectal and pancreatic cancers
Financial Impact
Significant potential value creation if trial succeeds, given unmet need in rare cancer and potential for dual approval pathway
Risk Factors
- Clinical trial execution risk in a rare cancer population
- Regulatory requirements may evolve despite current alignment
- Dependence on successful enrollment and funding for trial completion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000026 |
| Document: scacfdaalignment.htm | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index-headers.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026.txt | 0001129928-26-000026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access